China Biologic Products Inc. (NASDAQ:CBPO) shares saw an uptick in trading volume on Friday . 259,438 shares were traded during trading, an increase of 5% from the previous session’s volume of 247,744 shares.The stock last traded at $112.03 and had previously closed at $110.57.

Several research firms recently weighed in on CBPO. Jefferies Group reissued a “buy” rating on shares of China Biologic Products in a research report on Saturday, June 4th. Credit Suisse Group AG raised China Biologic Products from a “neutral” rating to an “outperform” rating in a research report on Tuesday, July 5th. Finally, Zacks Investment Research raised China Biologic Products from a “sell” rating to a “hold” rating in a research report on Thursday, May 19th.

The stock has a market capitalization of $3.02 billion and a PE ratio of 32.33. The company’s 50-day moving average is $117.43 and its 200-day moving average is $115.38.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.10. The firm earned $91.40 million during the quarter, compared to analyst estimates of $87.60 million. During the same period in the prior year, the business earned $1.06 EPS. The business’s revenue for the quarter was up 15.6% compared to the same quarter last year. Equities analysts expect that China Biologic Products Inc. will post $4.34 earnings per share for the current year.

In other China Biologic Products news, CFO Ming Yang sold 21,092 shares of China Biologic Products stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $124.32, for a total value of $2,622,157.44. Following the sale, the chief financial officer now owns 24,782 shares of the company’s stock, valued at approximately $3,080,898.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Zhijing Cbpo Liu sold 1,968 shares of China Biologic Products stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $124.32, for a total value of $244,661.76. The disclosure for this sale can be found here.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.